Osteoporosis therapy with denosumab in organ transplant recipients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F18%3A00076892" target="_blank" >RIV/00023001:_____/18:00076892 - isvavai.cz</a>

Result on the web

<a href="https://www.frontiersin.org/articles/10.3389/fendo.2018.00162/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fendo.2018.00162/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fendo.2018.00162" target="_blank" >10.3389/fendo.2018.00162</a>

Result language

angličtina

Original language name

Osteoporosis therapy with denosumab in organ transplant recipients

Original language description

Objective: Osteoporosis and fragility fractures represent serious complications for the solid organ transplant population. The recommended osteoporosis therapy for organ recipients involves supplementation with calcium and vitamin D and bisphosphonate administration. However, these options can prove limited for patients with impaired renal function. An alternative therapy option is offered by denosumab, a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand. Results: After denosumab therapy, L-spine T-scores improved across the whole group, ranging from -2.7 +/- 0.09 to -1.8 +/- 1.0 (p &lt; 0.001). T-score values for the proximal femur increased from -2.5 +/- 0.8 to -2.0 +/- 0.7 after the therapy (p &lt; 0.01). We observed only a mild, statistically insignificant improvement in distal forearm T-scores. The mean increase in L-spine bone mineral density (BMD) was 11.5 +/- 6.2% in subjects with osteoporosis at this site and 10.4 +/- 6.1% in the case of all patients. BMD of the proximal femur increased by 10.4 +/- 8.3% in patients with osteoporosis and by 7.5 +/- 7.3% in all patients. Denosumab therapy decreased the prevalence of osteoporosis in the L-spine from 75 to 27% (p &lt; 0.001) and proximal femur osteoporosis from 54 to 36% (p &lt; 0.05). Denosumab therapy reduced elevated levels of osteocalcin and beta-crosslaps (beta CTX) in comparison with baseline levels (p &lt; 0.001) across the whole group of graft recipients. Conclusion: Denosumab therapy was well-tolerated and improved bone density in our group of solid organ transplant recipients. The indications are that denosumab could be a viable therapeutic option for transplanted patients with osteoporosis, especially in those with renal function impairment or bisphosphonate intolerance.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in endocrinology

ISSN

1664-2392

e-ISSN

—

Volume of the periodical

9

Issue of the periodical within the volume

April

Country of publishing house

CH - SWITZERLAND

Number of pages

8

Pages from-to

"art. no. 162"

UT code for WoS article

000430203100001

EID of the result in the Scopus database

2-s2.0-85045727991